# Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

> **NCT02669017** · PHASE1 · COMPLETED · sponsor: **ADC Therapeutics S.A.** · enrollment: 183 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Burkitt's Lymphoma
- Chronic Lymphocytic Leukemia
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Lymphoma, Mantle-Cell
- Lymphoma, Marginal Zone
- Waldenstrom Macroglobulinemia
- Primary Mediastinal B-cell Lymphoma

## Interventions

- **DRUG:** ADCT-402

## Key facts

- **NCT ID:** NCT02669017
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-02-21
- **Final completion:** 2019-02-21
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669017, "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02669017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*